Physician profile
Mala Appachi
NPI 1306830369
$801.78
in general payments reported to CMS, 2019-2025
14 companies · $269 in 2025
The $269 reported for 2025 was more than what 82% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.13 · 2020: $20.75 · 2021: $148 · 2022: $99.22 · 2023: $70.32 · 2024: $182 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $520.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $179.84 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $133.98 | 2020-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Sanofi Pasteur INC. | $89.22 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $68.70 | 2021 | |
| Ironshore Pharmaceuticals INC. | $59.06 | 2019-2024 | |
| Cranial Technologies, INC | $50.84 | 2021-2023 | Doc Band |
| Pfizer INC. | $45.68 | 2024-2025 | |
| Seqirus USA INC | $44.65 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Alk-Abello, INC | $26.50 | 2025 | Ragwitek, Grastek, Odactra |
| Medtronic, INC. | $24.84 | 2025 | Intellis Adaptivestim |
| Abbvie INC. | $21.75 | 2023 | Vraylar |
| Corium, LLC | $20.88 | 2022 | |
| Novo Nordisk INC | $19.39 | 2021 | |
| Verrica Pharmaceuticals INC. | $16.45 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mala Appachi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.